Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

How we assessed the access potential of a new product in order to develop a successful launch strategy

How we assessed the access potential of a new product in order to develop a successful launch strategy

Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.

To ensure a fast and successful launch they wanted to develop key strategies to maximise acceptance and reimbursement of their product amongst HCPs and Payers. 

read more »

How integrated insights supported a biologic launch strategy across multiple indications

Our client is launching a new biologic in immunology across several indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and reimbursement as well the pricing opportunity. They wanted to use the insights to develop the optimal launch strategy across 12 markets and across indications, and also support the local market access teams by conducting a mock negotiation with payers.

read more »

  • Posted by Pei Li Teh
  • August 22, 2019
  • Videos

Conducting research for publication

Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their value to patients, healthcare and society.
 

read more »

  • Posted by Pei Li Teh
  • December 12, 2018
  • Webinars

Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies

Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies

Novel cancer therapies are offering patients new treatments and better outcomes worldwide. And recent changes in healthcare policies across APAC, such as China’s fast tracking approval of therapies for severe and rare diseases, have reignited interest in the APAC region as a strong market for oncology. 

read more »

Are dual ARVs the new frontier in a maturing HIV market?

Are dual ARVs the new frontier in a maturing HIV market?

Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.

Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.

read more »